Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life
Objective : To examine the efficacy and tolerability of escitalopram ( ESCIT ) compared to estrogen and progestogen therapy ( EPT ) for the treatment of symptomatic peri- and postmenopausal women . Design : Forty women ( aged 40 - 60 years ) with depressive disorders and menopause-related symptoms were r and omly assigned to an 8-week open trial with ESCIT ( flexible dose , 10 - 20 mg/day ; fixed dose , 10 mg/day for the first 4 weeks ) or estrogen plus progestogen therapy ( ethinyl estradiol 5 & mgr;g/day plus norethindrone acetate 1 mg/day ) . Primary outcome measures included Montgomery-Asberg Depression Rating Scale and the Greene Climacteric Scale at week 8 . Secondary outcome measures included the Clinical Global Impressions as well as sleep and quality of life assessment s. Results : Thirty-two women ( 16 on EPT , 16 on ESCIT ) were included in the analyses . Full remission of depression ( score of < 10 on the Montgomery-Asberg Depression Rating Scale ) was observed in 75 % ( 12/16 ) of subjects treated with ESCIT , compared to 25 % ( 4/16 ) treated with EPT ( P = 0.01 , Fisher 's exact tests ) . Remission of menopause-related symptoms ( > 50 % decrease in Greene Climacteric Scale scores ) was noted in 56 % ( 9/16 ) of women treated with ESCIT compared to 31.2 % ( 5/16 ) on EPT ( P = 0.03 , Pearson 's & khgr;2 tests ) . Improvement in sleep , hot flashes , and quality of life was observed with both treatments . Conclusions : ESCIT is more efficacious than EPT for the treatment of depression and has a positive impact on other menopause-related symptoms . ESCIT may constitute a treatment option for symptomatic menopausal women who are unable or unwilling to use hormone therapy
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .